Potential targeted therapy and diagnosis based on novel insight into growth factors, receptors, and downstream effectors in acute kidney injury and acute kidney injury-chronic kidney disease progression
Open Access
- 14 February 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Signal Transduction and Targeted Therapy
- Vol. 5 (1), 1-11
- https://doi.org/10.1038/s41392-020-0106-1
Abstract
Acute kidney injury (AKI) is defined as a rapid decline in renal function and is characterized by excessive renal inflammation and programmed death of resident cells. AKI shows high morbidity and mortality, and severe or repeated AKI can transition to chronic kidney disease (CKD) or even end-stage renal disease (ESRD); however, very few effective and specific therapies are available, except for supportive treatment. Growth factors, such as epidermal growth factor (EGF), insulin-like growth factor (IGF), and transforming growth factor-β (TGF-β), are significantly altered in AKI models and have been suggested to play critical roles in the repair process of AKI because of their roles in cell regeneration and renal repair. In recent years, a series of studies have shown evidence that growth factors, receptors, and downstream effectors may be highly involved in the mechanism of AKI and may function in the early stage of AKI in response to stimuli by regulating inflammation and programmed cell death. Moreover, certain growth factors or correlated proteins act as biomarkers for AKI due to their sensitivity and specificity. Furthermore, growth factors originating from mesenchymal stem cells (MSCs) via paracrine signaling or extracellular vesicles recruit leukocytes or repair intrinsic cells and may participate in AKI repair or the AKI-CKD transition. In addition, growth factor-modified MSCs show superior therapeutic potential compared to that of unmodified controls. In this review, we summarized the current therapeutic and diagnostic strategies targeting growth factors to treat AKI in clinical trials. We also evaluated the possibilities of other growth factor-correlated molecules as therapeutic targets in the treatment of AKI and the AKI-CKD transition.Keywords
This publication has 169 references indexed in Scilit:
- Human Wharton’s jelly-derived mesenchymal stromal cells reduce renal fibrosis through induction of native and foreign hepatocyte growth factor synthesis in injured tubular epithelial cellsStem Cell Research & Therapy, 2013
- Deletion of the epidermal growth factor receptor in renal proximal tubule epithelial cells delays recovery from acute kidney injuryKidney International, 2012
- Preischemic targeting of HIF prolyl hydroxylation inhibits fibrosis associated with acute kidney injuryAmerican Journal of Physiology-Renal Physiology, 2012
- Role of circulating fibroblast growth factor-2 in lipopolysaccharide-induced acute kidney injury in micePediatric Nephrology, 2011
- Genetic deficiency of Smad3 protects against murine ischemic acute kidney injuryAmerican Journal of Physiology-Renal Physiology, 2011
- MMP-9 gene deletion mitigates microvascular loss in a model of ischemic acute kidney injuryAmerican Journal of Physiology-Renal Physiology, 2011
- Targeting Endothelium-Pericyte Cross Talk by Inhibiting VEGF Receptor Signaling Attenuates Kidney Microvascular Rarefaction and FibrosisThe American Journal of Pathology, 2011
- The role of the EGF family of ligands and receptors in renal development, physiology and pathophysiologyExperimental Cell Research, 2009
- VEGF-121 preserves renal microvessel structure and ameliorates secondary renal disease following acute kidney injuryAmerican Journal of Physiology-Renal Physiology, 2008
- The endothelial cell in ischemic acute kidney injury: implications for acute and chronic functionKidney International, 2007